Document is current
Any future updates will be listed below
-
Authors
Wang, Lu
Nuñez, Yaira Z.
Martínez-Magaña, José Jaime
Rivera-Hernandez, Melody https://orcid.org/0009-0005-5551-2075
Mao, Zhongzheng https://orcid.org/0009-0001-0800-380X
Brennand, Kristen J. https://orcid.org/0000-0003-0993-5956
Montalvo-Ortiz, Janitza L. https://orcid.org/0000-0002-7657-8365
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Zhou, Hang https://orcid.org/0000-0002-7694-6391
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (U54 AA027989, R01 AA030056, R01 AA026364, R01 AA011330, P50 AA012870)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG011558)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R21 DA063120, P30 DA046345, R01 DA037974, DP1 DA058737)
Office of Research and Development (I01 BX004820, 1I01CX001849)
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 28 July 2025
Accepted: 27 August 2025
First Online: 6 October 2025
Competing interests
: J.G. is paid for his editorial work on the journal Complex Psychiatry. H.R.K. is a member of advisory boards for Altimmune, Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Altimmune and Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics.
